Ruxolitinib Rutinib Cream 1.5% is an advanced topical medication specifically formulated for the treatment of atopic dermatitis (eczema) and vitiligo. This cream harnesses the power of Ruxolitinib, a potent Janus kinase (JAK) inhibitor, which acts by modulating the immune system's hyperactive inflammatory responses responsible for skin inflammation and depigmentation. By targeting JAK enzymes, it helps to both reduce inflammation and promote repigmentation of the skin in vitiligo patients. Intended for direct application on affected skin areas, it requires a prescription and the treatment regimen should strictly follow healthcare provider's instructions to maximize therapeutic efficacy while minimizing adverse effects. Manufactured with stringent quality assurance protocols, Ruxolitinib Rutinib Cream 1.5% guarantees consistency, safety, and dermatological compatibility. It is a specialized solution for healthcare professionals seeking an effective and scientifically validated topical treatment for managing chronic inflammatory skin disorders and pigmentary irregularities.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ruxolitinib 1.5% |
| Mechanism of Action | Janus kinase (JAK) enzyme inhibition |
| Indications | Atopic dermatitis (eczema), vitiligo |
| Formulation | Topical cream |
| Application | Direct application on affected skin areas as prescribed |
| Prescription Status | Prescription only |
| Manufacturing Standards | Produced under strict quality controls |
| Therapeutic Benefits | Reduces inflammation and promotes skin repigmentation |
| Safety Profile | Established safety with recommended medical supervision |
| Packaging | Sealed cream tubes with dosage instructions |
| Attributes | Description |
|---|---|
| Concentration | 1.5% Ruxolitinib |
| Dosage Form | Cream |
| Intended Use | Topical treatment of eczema and vitiligo |
| Pharmacological Class | JAK inhibitor |
| Storage Conditions | Store at controlled room temperature, away from moisture and light |
| Shelf Life | Typically 24 months from manufacturing date |
| Instructions for Use | Apply as directed by a healthcare professional on affected skin |
| Prescription Requirement | Mandatory prescription by registered healthcare provider |
| Manufacturing Compliance | Conforms to GMP standards and dermatological safety norms |
| Country of Origin | India |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Ruxolitinib Rutinib Cream 1.5% is prescribed for treating atopic dermatitis (eczema) and vitiligo by reducing inflammation and promoting skin repigmentation.
Ruxolitinib inhibits Janus kinase (JAK) enzymes, modulating the immune response which decreases skin inflammation and encourages repigmentation in vitiligo-affected areas.
Ruxolitinib Rutinib Cream is a prescription-only topical medication and must be used under medical supervision.
The cream should be stored at controlled room temperature, away from moisture and direct light to preserve its stability and effectiveness.
Ruxolitinib Rutinib Cream is specifically approved for eczema and vitiligo; use for other conditions should only be under explicit medical guidance.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
